Establishing a Framework for Conducting Multiple Myeloma Clinical Trials

Objectives
Discusses and clarifies procedures and guidelines for developing future multiple myeloma clinical trials to help expedite drug development, and speed the delivery of much needed therapies to the patient.

Chair
Kenneth C. Anderson, MD
Director, Jerome Lipper Multiple Myeloma Center
Medical Director, Kraft Family Donor Center
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute

Sponsors
Human Genome Sciences, Inc.
Celgene Corporation
Millennium Pharmaceuticals
Novartis Pharmaceuticals Corporation

Read Development of Effective New Treatments for Myeloma, the resulting article from the Journal of Clinical Oncology.

Download Abstracts